trending Market Intelligence /marketintelligence/en/news-insights/trending/McdVpZXnQw6ig0t9GT8rGQ2 content esgSubNav
In This List

Tracking mosquito viruses, CRISPR-ing mice tumors; FDA shutdown may enter 2019


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Tracking mosquito viruses, CRISPR-ing mice tumors; FDA shutdown may enter 2019

Here are the editors' top picks for the week ended Dec. 28.

Of Mice Not Men: Tracking mosquito viruses; CRISPR-ing obesity and tumors

In this week's column, scientists looked to mosquitoes' stomachs to track the transmission of viruses, an Alzheimer's protein was found in contaminated brain tissue extracts, and CRISPR mitigated obesity and chemotherapy resistance in mice.

Capitol Checkup: Both sides want speedy ACA appeal; FDA shutdown may go to 2019

Both sides in the legal battle over the constitutionality of the Affordable Care Act want the case to promptly move forward to an appeal; meanwhile, the head of the U.S. Food and Drug Administration tried to reassure Americans during the shutdown.

EU agency recommends 84 new medicines in 2018; reviews heart drugs with impurity

The European Medicines Agency recommended 84 new medicines for marketing authorization in 2018 and initiated the review of a hypertension drug after finding traces of a potential cancer-causing compound.

Junshi stock surges to HK$23.75 per share in Hong Kong debut

The Shanghai-based company in December received approval to produce China's first homemade PD-1 class of checkpoint inhibitors.

Medicaid agency approves work requirement programs for Michigan, Maine

The Centers for Medicare and Medicaid Services has approved work requirement waivers for Maine and Michigan, increasing the number of states to have work requirement programs approved to seven.

Medicare agency finalizes changes to shared savings program for provider groups

The Centers for Medicare and Medicaid Services finalized the agency's restructuring of the accountable care organization shared savings program. The agency also increased certain savings rates from their levels in the August proposed rule.

US price watchdog: Novartis' gene therapy is better value than Biogen rival

The Institute for Clinical and Economic Review has found that a new gene therapy from Novartis AG is more cost-effective than Biogen Inc.'s Spinraza in treating a rare, debilitating infant disease called spinal muscular atrophy.